{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:07:17Z","timestamp":1768565237467,"version":"3.49.0"},"posted":{"date-parts":[[2024,1,12]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":17,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,2,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Over a six-month span, three patients under five years old with cutaneous leishmaniasis presented to the Pediatric Infectious Diseases Clinic at the University of Texas Southwestern Medical Center\/Children\u2019s Health Dallas. None had traveled outside of the United States (US); all had confirmed\n                  <jats:italic>L. mexicana<\/jats:italic>\n                  infections by PCR. We provide case descriptions and images to increase the awareness of this disease among US physicians and scientists. Two patients responded to fluconazole, but one required topical paromomycin. Combining these cases with guidelines and our literature review, we suggest that: 1) higher doses (ten-twelve mg\/kg\/day) of fluconazole should be considered in young children to maximize likelihood and rapidity of response and 2) patients should transition to alternate agents if they do not respond to high-dose fluconazole within six weeks. Furthermore, and of particular interest to the broad microbiology community, we used samples from these cases as a proof-of-concept to propose a mechanism to strain-type US-endemic\n                  <jats:italic>L. mexicana.<\/jats:italic>\n                  For our analysis, we sequenced three housekeeping genes and the internal transcribed sequence 2 of the ribosomal RNA gene. We identified genetic changes that not only allow us to distinguish US-based\n                  <jats:italic>L. mexicana<\/jats:italic>\n                  strains from strains found in other areas of the Americas, but also establish polymorphisms that differ between US isolates. These techniques will allow documentation of genetic changes in this parasite as its range expands. Hence, our cases of cutaneous leishmaniasis provide significant evolutionary, treatment and public health implications as climate change increases exposure to formerly tropical diseases in previously non-endemic areas.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>IMPORTANCE<\/jats:title>\n                  <jats:p>\n                    Leishmaniasis is a parasitic disease that typically affects tropical regions worldwide. However, the vector that carries\n                    <jats:italic>Leishmania<\/jats:italic>\n                    is spreading northward into the United States (US). Within a six-month period, three young cutaneous leishmaniasis patients were seen at the Pediatric Infectious Diseases Clinic at The University of Texas Southwestern\/Children\u2019s Health Dallas. None had traveled outside of north Texas. We document their presentations, treatments, and outcomes and compare their management to clinical practice guidelines for leishmaniasis. We also analyzed the sequences of three critical genes in\n                    <jats:italic>Leishmania mexicana<\/jats:italic>\n                    isolated from these patients. We found changes that not only distinguish US-based strains from strains found elsewhere, but also differ between US isolates. Monitoring these sequences will allow tracking of genetic changes in parasites over time. Our findings have significant US public health implications as people are increasingly likely to be exposed to what were once tropical diseases.\n                  <\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.01.11.23300611","type":"posted-content","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T21:00:17Z","timestamp":1705093217000},"source":"Crossref","is-referenced-by-count":2,"title":["Cutaneous\n                  <i>Leishmania mexicana<\/i>\n                  Infections in the United States: Defining Strains Through Endemic Human Pediatric Cases in Northern Texas"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3844-3491","authenticated-orcid":false,"given":"Binita","family":"Nepal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8198-1143","authenticated-orcid":false,"given":"Clare","family":"McCormick-Baw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-9760","authenticated-orcid":false,"given":"Karisma","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2608-5447","authenticated-orcid":false,"given":"Sarah","family":"Firmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3990-7043","authenticated-orcid":false,"given":"Dawn M.","family":"Wetzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024021823350870000_2024.01.11.23300611v2.1","unstructured":"Wetzel DM , Phillips MA . Chapter 67: Chemotherapy of protozoal infections: amebiasis, giardiasis, trichomoniasis, trypanosomiasis, leishmaniasis, and other protozoal infections. In: Brunton L, editor. Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics. 13 ed. New York, NY: McGraw-Hill Medical; 2023. p. 1309-24."},{"key":"2024021823350870000_2024.01.11.23300611v2.2","unstructured":"https:\/\/www.cdc.gov\/dpdx\/leishmaniasis\/index.html."},{"key":"2024021823350870000_2024.01.11.23300611v2.3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000585"},{"key":"2024021823350870000_2024.01.11.23300611v2.4","doi-asserted-by":"publisher","DOI":"10.1053\/j.tcam.2009.06.006"},{"key":"2024021823350870000_2024.01.11.23300611v2.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.11.008"},{"issue":"9","key":"2024021823350870000_2024.01.11.23300611v2.6","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/jamadermatol.2018.2133","article-title":"Incidence of endemic human cutaneous leishmaniasis in the United States","volume":"154","year":"2018","journal-title":"JAMA Dermatol"},{"key":"2024021823350870000_2024.01.11.23300611v2.7","doi-asserted-by":"crossref","unstructured":"Aronson N , Herwaldt BL , Libman M , Pearson R , Lopez-Velez R , Weina P , et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg. 2016 Dec 07.","DOI":"10.4269\/ajtmh.16-84256"},{"key":"2024021823350870000_2024.01.11.23300611v2.8","doi-asserted-by":"crossref","unstructured":"de Almeida ME , Steurer FJ , Koru O , Herwaldt BL , Pieniazek NJ , da Silva AJ . Identification of Leishmania spp. by molecular amplification and DNA sequencing analysis of a fragment of rRNA internal transcribed spacer 2. J Clin Microbiol. 2011 Sep;49(9):3143-9.","DOI":"10.1128\/JCM.01177-11"},{"key":"2024021823350870000_2024.01.11.23300611v2.9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw662"},{"key":"2024021823350870000_2024.01.11.23300611v2.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011882"},{"issue":"6 Pt 2","key":"2024021823350870000_2024.01.11.23300611v2.11","first-page":"S14","article-title":"Pharmacokinetics of fluconazole in skin and nails","volume":"40","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"2024021823350870000_2024.01.11.23300611v2.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1993.tb00987.x"},{"issue":"5","key":"2024021823350870000_2024.01.11.23300611v2.13","first-page":"15761","article-title":"Clinical pharmacology of fluconazole in infants and children","volume":"10","year":"2020","journal-title":"Clin Med Investig"},{"key":"2024021823350870000_2024.01.11.23300611v2.14","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.earlhumdev.2011.01.014","article-title":"Pharmacokinetics of antifungal agents in children","volume":"87","year":"2011","journal-title":"Early Hum Dev"},{"key":"2024021823350870000_2024.01.11.23300611v2.15","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e31819f1f50"},{"key":"2024021823350870000_2024.01.11.23300611v2.16","doi-asserted-by":"publisher","DOI":"10.1101\/gr.122945.111"},{"issue":"1","key":"2024021823350870000_2024.01.11.23300611v2.17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.molbiopara.2006.04.010","article-title":"Functional characterization and subcellular localization of the three malate dehydrogenase isozymes in Leishmania spp","volume":"149","year":"2006","journal-title":"Mol Biochem Parasitol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.01.11.23300611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:48:12Z","timestamp":1768506492000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.01.11.23300611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,12]]},"references-count":17,"URL":"https:\/\/doi.org\/10.1101\/2024.01.11.23300611","relation":{},"subject":[],"published":{"date-parts":[[2024,1,12]]},"subtype":"preprint"}}